Recent advances, challenges and updates on the development of therapeutics for malaria




antimalarials, clinical trials, malaria, tafenoquine, cipargamin, artefenomel


Malaria has developed as a serious worldwide health issue as a result of the introduction of resistant Plasmodium species strains. Because of the common chemo resistance to most of the existing drugs on the market, it poses a severe health problem and significant obstacles in drug research. Malaria treatment has evolved during the last two decades in response to Plasmodium falciparum drug sensitivity and a return of the disease in tropical areas. Plasmodium falciparum is now highly resistant to the majority of antimalarial drugs. The parasite resistance drew focus to developing novel antimalarials to combat parasite resistance. The requirement for many novel antimalarial drugs in the future year necessitates adopting various drug development methodologies. Different innovative strategies for discovering antimalarial drugs are now being examined here. This review is primarily concerned with the description of newly synthesized antimalarial compounds, i.e. Tafenoquine, Cipargamin, Ferroquine, Artefenomel, DSM265, MMV390048 designed to improve the activity of pure antimalarial enantiomers. In this review, we selected the representative malarial drugs in clinical trials, classified them with detailed targets according to their action, discussed the relationship within the human trials, and generated a summative discussion with prospective expectations.



How to Cite

Nandal, R., Kumar, D., Aggarwal, N., Kumar, V., Narasimhan, B., Marwaha, R. K., … Deep, A. (2024). Recent advances, challenges and updates on the development of therapeutics for malaria . EXCLI Journal, 23, 672–713.



Review articles


Most read articles by the same author(s)